請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57523
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊雅倩(Ya-Chien Yang) | |
dc.contributor.author | Che-Wei Chang | en |
dc.contributor.author | 張哲瑋 | zh_TW |
dc.date.accessioned | 2021-06-16T06:49:49Z | - |
dc.date.available | 2019-10-09 | |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-07-24 | |
dc.identifier.citation | 1. Abraham, C. and J.H. Cho. Inflammatory bowel disease. N Engl J Med, 2009. 361(21): p. 2066-78.
2. Molodecky, N.A., I.S. Soon, D.M. Rabi, W.A. Ghali, M. Ferris, G. Chernoff et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46-54 e42; quiz e30. 3. Kaser, A., S. Zeissig, and R.S. Blumberg. Inflammatory bowel disease. Annu Rev Immunol, 2010. 28: p. 573-621. 4. Ordás, I., L. Eckmann, M. Talamini, D.C. Baumgart, and W.J. Sandborn. Ulcerative colitis. The Lancet, 2012. 380(9853): p. 1606-1619. 5. Baumgart, D.C. and W.J. Sandborn. Crohn's disease. The Lancet, 2012. 380(9853): p. 1590-1605. 6. Baumgart, D.C. and S.R. Carding. Inflammatory bowel disease: cause and immunobiology. The Lancet, 2007. 369(9573): p. 1627-1640. 7. Buhner, S., C. Buning, J. Genschel, K. Kling, D. Herrmann, A. Dignass et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut, 2006. 55(3): p. 342-7. 8. Macdonald, T.T. and G. Monteleone. Immunity, inflammation, and allergy in the gut. Science, 2005. 307(5717): p. 1920-5. 9. Loftus, E.V., Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 2004. 126(6): p. 1504-17. 10. Lakatos, P.L., T. Szamosi, and L. Lakatos. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol, 2007. 13(46): p. 6134-9. 11. Cosnes, J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol, 2004. 18(3): p. 481-96. 12. Sakamoto, N., S. Kono, K. Wakai, Y. Fukuda, M. Satomi, T. Shimoyama et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis, 2005. 11(2): p. 154-63. 13. Persson, P.G., A. Ahlbom, and G. Hellers. Diet and inflammatory bowel disease: a case-control study. Epidemiology, 1992. 3(1): p. 47-52. 14. Andersen, V., A. Olsen, F. Carbonnel, A. Tjonneland, and U. Vogel. Diet and risk of inflammatory bowel disease. Dig Liver Dis, 2012. 44(3): p. 185-94. 15. Hou, J.K., D. Lee, and J. Lewis. Diet and Inflammatory Bowel Disease: Review of Patient-Targeted Recommendations. Clin Gastroenterol Hepatol, 2013. 16. Bernstein, C.N. and F. Shanahan. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut, 2008. 57(9): p. 1185-91. 17. Head, K. and J.S. Jurenka. Inflammatory bowel disease. Part II: Crohn's disease--pathophysiology and conventional and alternative treatment options. Altern Med Rev, 2004. 9(4): p. 360-401. 18. Head, K.A. and J.S. Jurenka. Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Altern Med Rev, 2003. 8(3): p. 247-83. 19. Behr, M.A. and E. Schurr. Mycobacteria in Crohn's disease: a persistent hypothesis. Inflamm Bowel Dis, 2006. 12(10): p. 1000-4. 20. Gkouskou, K.K., C. Deligianni, C. Tsatsanis, and A.G. Eliopoulos. The gut microbiota in mouse models of inflammatory bowel disease. Front Cell Infect Microbiol, 2014. 4: p. 28. 21. Jernberg, C., S. Lofmark, C. Edlund, and J.K. Jansson. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J, 2007. 1(1): p. 56-66. 22. Noverr, M.C. and G.B. Huffnagle. Does the microbiota regulate immune responses outside the gut? Trends Microbiol, 2004. 12(12): p. 562-8. 23. Ng, S.C., W. Tang, J.Y. Ching, M. Wong, C.M. Chow, A.J. Hui et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology, 2013. 145(1): p. 158-165 e2. 24. Zeng, Z., Z. Zhu, Y. Yang, W. Ruan, X. Peng, Y. Su et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol, 2013. 28(7): p. 1148-53. 25. Hou, J.K., H. El-Serag, and S. Thirumurthi. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol, 2009. 104(8): p. 2100-9. 26. Hou, J.K., J.R. Kramer, P. Richardson, M. Mei, and H.B. El-Serag. The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study. Inflamm Bowel Dis, 2013. 19(5): p. 1059-64. 27. Wei, S.C., M.J. Shieh, M.C. Chang, Y.T. Chang, C.Y. Wang, and J.M. Wong. Long-term follow-up of ulcerative colitis in Taiwan. J Chin Med Assoc, 2012. 75(4): p. 151-5. 28. Lu, C.L. Ulcerative colitis in Taiwan: a potentially rising burden. J Chin Med Assoc, 2012. 75(6): p. 247-8. 29. Chuang, C.H., S.H. Lin, C.Y. Chen, B.S. Sheu, A.W. Kao, and J.D. Wang. Increasing Incidence and Lifetime Risk of Inflammatory Bowel Disease in Taiwan: A Nationwide Study in a Low-endemic Area 1998-2010. Inflamm Bowel Dis, 2013. 30. Geremia, A., P. Biancheri, P. Allan, G.R. Corazza, and A. Di Sabatino. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev, 2013. 13(1): p. 3-10. 31. Van der Sluis, M., B.A. De Koning, A.C. De Bruijn, A. Velcich, J.P. Meijerink, J.B. Van Goudoever et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology, 2006. 131(1): p. 117-29. 32. Velcich, A., W. Yang, J. Heyer, A. Fragale, C. Nicholas, S. Viani et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science, 2002. 295(5560): p. 1726-9. 33. Salim, S.Y. and J.D. Soderholm. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis, 2011. 17(1): p. 362-81. 34. Uehara, A., Y. Fujimoto, K. Fukase, and H. Takada. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol, 2007. 44(12): p. 3100-11. 35. Lapis, K. [Role of antimicrobial peptides (AMP) and pattern recognition receptors (PRR) in the intestinal mucosa homeostasis]. Orv Hetil, 2009. 150(47): p. 2146-9. 36. Muniz, L.R., C. Knosp, and G. Yeretssian. Intestinal antimicrobial peptides during homeostasis, infection, and disease. Front Immunol, 2012. 3: p. 310. 37. Sotolongo, J., C. Espana, A. Echeverry, D. Siefker, N. Altman, J. Zaias et al. Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity. J Exp Med, 2011. 208(13): p. 2705-16. 38. Lavelle, E.C., C. Murphy, L.A. O'Neill, and E.M. Creagh. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol, 2010. 3(1): p. 17-28. 39. Akira, S., S. Uematsu, and O. Takeuchi. Pathogen recognition and innate immunity. Cell, 2006. 124(4): p. 783-801. 40. Clarke, T.B. and J.N. Weiser. Intracellular sensors of extracellular bacteria. Immunol Rev, 2011. 243(1): p. 9-25. 41. Martinon, F., A. Mayor, and J. Tschopp. The inflammasomes: guardians of the body. Annu Rev Immunol, 2009. 27: p. 229-65. 42. Russ, B.E., J.E. Prier, S. Rao, and S.J. Turner. T cell immunity as a tool for studying epigenetic regulation of cellular differentiation. Front Genet, 2013. 4: p. 218. 43. Kanhere, A., A. Hertweck, U. Bhatia, M.R. Gokmen, E. Perucha, I. Jackson et al. T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat Commun, 2012. 3: p. 1268. 44. Korn, T., E. Bettelli, M. Oukka, and V.K. Kuchroo. IL-17 and Th17 Cells. Annu Rev Immunol, 2009. 27: p. 485-517. 45. Fuss, I.J., M. Neurath, M. Boirivant, J.S. Klein, C. de la Motte, S.A. Strong et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol, 1996. 157(3): p. 1261-70. 46. Geremia, A. and D.P. Jewell. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol, 2012. 6(2): p. 223-37. 47. Romagnani, S. Lymphokine production by human T cells in disease states. Annu Rev Immunol, 1994. 12: p. 227-57. 48. Pizarro, T.T., M.H. Michie, M. Bentz, J. Woraratanadharm, M.F. Smith, Jr., E. Foley et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol, 1999. 162(11): p. 6829-35. 49. Monteleone, G., L. Biancone, R. Marasco, G. Morrone, O. Marasco, F. Luzza et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology, 1997. 112(4): p. 1169-78. 50. Breese, E., C.P. Braegger, C.J. Corrigan, J.A. Walker-Smith, and T.T. MacDonald. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology, 1993. 78(1): p. 127-31. 51. Noguchi, M., N. Hiwatashi, Z. Liu, and T. Toyota. Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. J Gastroenterol, 1995. 30 Suppl 8: p. 52-5. 52. Heller, F., P. Florian, C. Bojarski, J. Richter, M. Christ, B. Hillenbrand et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology, 2005. 129(2): p. 550-64. 53. Fuss, I.J., F. Heller, M. Boirivant, F. Leon, M. Yoshida, S. Fichtner-Feigl et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest, 2004. 113(10): p. 1490-7. 54. Di Sabatino, A., P. Biancheri, L. Rovedatti, T.T. MacDonald, and G.R. Corazza. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis, 2012. 18(2): p. 368-71. 55. Rovedatti, L., T. Kudo, P. Biancheri, M. Sarra, C.H. Knowles, D.S. Rampton et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut, 2009. 58(12): p. 1629-36. 56. Kadivar, K., E.D. Ruchelli, J.E. Markowitz, M.L. Defelice, M.L. Strogatz, M.M. Kanzaria et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis, 2004. 10(5): p. 593-8. 57. Zhou, L., Ivanov, II, R. Spolski, R. Min, K. Shenderov, T. Egawa et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol, 2007. 8(9): p. 967-74. 58. Sarra, M., F. Pallone, T.T. Macdonald, and G. Monteleone. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis, 2010. 16(10): p. 1808-13. 59. Harrington, L.E., R.D. Hatton, P.R. Mangan, H. Turner, T.L. Murphy, K.M. Murphy et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 2005. 6(11): p. 1123-32. 60. Annunziato, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi et al. Phenotypic and functional features of human Th17 cells. J Exp Med, 2007. 204(8): p. 1849-61. 61. Kobayashi, T., S. Okamoto, T. Hisamatsu, N. Kamada, H. Chinen, R. Saito et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut, 2008. 57(12): p. 1682-9. 62. Sugihara, T., A. Kobori, H. Imaeda, T. Tsujikawa, K. Amagase, K. Takeuchi et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol, 2010. 160(3): p. 386-93. 63. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 2003. 52(1): p. 65-70. 64. Shevach, E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity, 2009. 30(5): p. 636-45. 65. Menager-Marcq, I., C. Pomie, P. Romagnoli, and J.P. van Meerwijk. CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology, 2006. 131(6): p. 1775-85. 66. Fantini, M.C., C. Becker, I. Tubbe, A. Nikolaev, H.A. Lehr, P. Galle et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut, 2006. 55(5): p. 671-80. 67. Chamouard, P., F. Monneaux, Z. Richert, A.C. Voegeli, T. Lavaux, M.P. Gaub et al. Diminution of Circulating CD4+CD25 high T cells in naive Crohn's disease. Dig Dis Sci, 2009. 54(10): p. 2084-93. 68. Singh, B., S. Read, C. Asseman, V. Malmstrom, C. Mottet, L.A. Stephens et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev, 2001. 182: p. 190-200. 69. Lee, Y.K., R. Mukasa, R.D. Hatton, and C.T. Weaver. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol, 2009. 21(3): p. 274-80. 70. Fahlen, L., S. Read, L. Gorelik, S.D. Hurst, R.L. Coffman, R.A. Flavell et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med, 2005. 201(5): p. 737-46. 71. Monteleone, G., A. Kumberova, N.M. Croft, C. McKenzie, H.W. Steer, and T.T. MacDonald. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest, 2001. 108(4): p. 601-9. 72. Fantini, M.C., A. Rizzo, D. Fina, R. Caruso, M. Sarra, C. Stolfi et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology, 2009. 136(4): p. 1308-16, e1-3. 73. Rubin, D.C., A. Shaker, and M.S. Levin. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol, 2012. 3: p. 107. 74. Rogler, G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett, 2013. 75. Lakatos, P.L. and L. Lakatos. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol, 2008. 14(25): p. 3937-47. 76. Eaden, J.A., K.R. Abrams, and J.F. Mayberry. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 2001. 48(4): p. 526-35. 77. De Robertis, M., E. Massi, M.L. Poeta, S. Carotti, S. Morini, L. Cecchetelli et al. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog, 2011. 10: p. 9. 78. Tanaka, T., H. Kohno, R. Suzuki, Y. Yamada, S. Sugie, and H. Mori. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci, 2003. 94(11): p. 965-73. 79. Barderas, R., R. Villar-Vazquez, M.J. Fernandez-Acenero, I. Babel, A. Pelaez-Garcia, S. Torres et al. Sporadic colon cancer murine models demonstrate the value of autoantibody detection for preclinical cancer diagnosis. Sci Rep, 2013. 3: p. 2938. 80. Meira, L.B., J.M. Bugni, S.L. Green, C.W. Lee, B. Pang, D. Borenshtein et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest, 2008. 118(7): p. 2516-25. 81. Yang, L., N. Belaguli, and D.H. Berger. MicroRNA and colorectal cancer. World J Surg, 2009. 33(4): p. 638-46. 82. Kanaan, Z., S.N. Rai, M.R. Eichenberger, C. Barnes, A.M. Dworkin, C. Weller et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat, 2012. 33(3): p. 551-60. 83. Grivennikov, S.I. and M. Karin. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev, 2010. 21(1): p. 11-9. 84. Erreni, M., A. Mantovani, and P. Allavena. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron, 2011. 4(2): p. 141-54. 85. Grivennikov, S.I. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol, 2013. 35(2): p. 229-44. 86. Haggar, F.A. and R.P. Boushey. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg, 2009. 22(4): p. 191-7. 87. Kitisin, K. and L. Mishra. Molecular biology of colorectal cancer: new targets. Semin Oncol, 2006. 33(6 Suppl 11): p. S14-23. 88. Walther, A., E. Johnstone, C. Swanton, R. Midgley, I. Tomlinson, and D. Kerr. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer, 2009. 9(7): p. 489-99. 89. Arends, M.J. Pathways of colorectal carcinogenesis. Appl Immunohistochem Mol Morphol, 2013. 21(2): p. 97-102. 90. Bodmer, W.F. Cancer genetics: colorectal cancer as a model. J Hum Genet, 2006. 51(5): p. 391-6. 91. Pino, M.S. and D.C. Chung. The chromosomal instability pathway in colon cancer. Gastroenterology, 2010. 138(6): p. 2059-72. 92. Soreide, K. [Genetics and molecular classification of colorectal cancer]. Tidsskr Nor Laegeforen, 2007. 127(21): p. 2818-23. 93. Shivapurkar, N., A. Maitra, S. Milchgrub, and A.F. Gazdar. Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol, 2001. 32(2): p. 169-77. 94. Boland, C.R. and A. Goel. Microsatellite instability in colorectal cancer. Gastroenterology, 2010. 138(6): p. 2073-2087 e3. 95. Kim, M.S., J. Lee, and D. Sidransky. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev, 2010. 29(1): p. 181-206. 96. Perse, M. and A. Cerar. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol, 2012. 2012: p. 718617. 97. Whittem, C.G., A.D. Williams, and C.S. Williams. Murine Colitis modeling using Dextran Sulfate Sodium (DSS). J Vis Exp, 2010(35). 98. Johansson, M.E., J.K. Gustafsson, K.E. Sjoberg, J. Petersson, L. Holm, H. Sjovall et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One, 2010. 5(8): p. e12238. 99. Araki, Y., K. Mukaisyo, H. Sugihara, Y. Fujiyama, and T. Hattori. Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncol Rep, 2010. 24(4): p. 869-74. 100. Laroui, H., S.A. Ingersoll, H.C. Liu, M.T. Baker, S. Ayyadurai, M.A. Charania et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS One, 2012. 7(3): p. e32084. 101. Bauer, C., P. Duewell, C. Mayer, H.A. Lehr, K.A. Fitzgerald, M. Dauer et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut, 2010. 59(9): p. 1192-9. 102. Iba, Y., Y. Sugimoto, and C. Kamei. Participation of mast cells in colitis inflammation induced by dextran sulfate sodium. Methods Find Exp Clin Pharmacol, 2002. 24(1): p. 15-8. 103. Alex, P., N.C. Zachos, T. Nguyen, L. Gonzales, T.E. Chen, L.S. Conklin et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis, 2009. 15(3): p. 341-52. 104. Papadakis, K.A. and S.R. Targan. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med, 2000. 51: p. 289-98. 105. Okayasu, I., S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 1990. 98(3): p. 694-702. 106. Cooper, H.S., S.N. Murthy, R.S. Shah, and D.J. Sedergran. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest, 1993. 69(2): p. 238-49. 107. Aikawa, J., K. Grobe, M. Tsujimoto, and J.D. Esko. Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase. Structure and activity of the fourth member, NDST4. J Biol Chem, 2001. 276(8): p. 5876-82. 108. Orellana, A., C.B. Hirschberg, Z. Wei, S.J. Swiedler, and M. Ishihara. Molecular cloning and expression of a glycosaminoglycan N-acetylglucosaminyl N-deacetylase/N-sulfotransferase from a heparin-producing cell line. J Biol Chem, 1994. 269(3): p. 2270-6. 109. Esko, J.D. and S.B. Selleck. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem, 2002. 71: p. 435-71. 110. Sarrazin, S., W.C. Lamanna, and J.D. Esko. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol, 2011. 3(7). 111. Bishop, J.R., M. Schuksz, and J.D. Esko. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature, 2007. 446(7139): p. 1030-7. 112. Lin, X., E.M. Buff, N. Perrimon, and A.M. Michelson. Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development, 1999. 126(17): p. 3715-23. 113. Toyoda, H., A. Kinoshita-Toyoda, B. Fox, and S.B. Selleck. Structural analysis of glycosaminoglycans in animals bearing mutations in sugarless, sulfateless, and tout-velu. Drosophila homologues of vertebrate genes encoding glycosaminoglycan biosynthetic enzymes. J Biol Chem, 2000. 275(29): p. 21856-61. 114. Fan, G., L. Xiao, L. Cheng, X. Wang, B. Sun, and G. Hu. Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett, 2000. 467(1): p. 7-11. 115. Ringvall, M., J. Ledin, K. Holmborn, T. van Kuppevelt, F. Ellin, I. Eriksson et al. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1. J Biol Chem, 2000. 275(34): p. 25926-30. 116. Forsberg, E., G. Pejler, M. Ringvall, C. Lunderius, B. Tomasini-Johansson, M. Kusche-Gullberg et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature, 1999. 400(6746): p. 773-6. 117. Humphries, D.E., G.W. Wong, D.S. Friend, M.F. Gurish, W.T. Qiu, C. Huang et al. Heparin is essential for the storage of specific granule proteases in mast cells. Nature, 1999. 400(6746): p. 769-72. 118. Pallerla, S.R., R. Lawrence, L. Lewejohann, Y. Pan, T. Fischer, U. Schlomann et al. Altered heparan sulfate structure in mice with deleted NDST3 gene function. J Biol Chem, 2008. 283(24): p. 16885-94. 119. Lortat-Jacob, H., A. Grosdidier, and A. Imberty. Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci U S A, 2002. 99(3): p. 1229-34. 120. Proudfoot, A.E., T.M. Handel, Z. Johnson, E.K. Lau, P. LiWang, I. Clark-Lewis et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A, 2003. 100(4): p. 1885-90. 121. Matsuo, I. and C. Kimura-Yoshida. Extracellular modulation of Fibroblast Growth Factor signaling through heparan sulfate proteoglycans in mammalian development. Curr Opin Genet Dev, 2013. 23(4): p. 399-407. 122. Schenauer, M.R., Y. Yu, M.D. Sweeney, and J.A. Leary. CCR2 chemokines bind selectively to acetylated heparan sulfate octasaccharides. J Biol Chem, 2007. 282(35): p. 25182-8. 123. Lantz, M., H. Thysell, E. Nilsson, and I. Olsson. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest, 1991. 88(6): p. 2026-31. 124. Lortat-Jacob, H. and J.A. Grimaud. Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett, 1991. 280(1): p. 152-4. 125. Hermano, E., I. Lerner, and M. Elkin. Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell Mol Life Sci, 2012. 69(15): p. 2501-13. 126. Lee, J.S. and C.B. Chien. When sugars guide axons: insights from heparan sulphate proteoglycan mutants. Nat Rev Genet, 2004. 5(12): p. 923-35. 127. Parish, C.R. The role of heparan sulphate in inflammation. Nat Rev Immunol, 2006. 6(9): p. 633-43. 128. Iozzo, R.V. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol, 2005. 6(8): p. 646-56. 129. Kolset, S.O. and H. Tveit. Serglycin--structure and biology. Cell Mol Life Sci, 2008. 65(7-8): p. 1073-85. 130. Hacker, U., K. Nybakken, and N. Perrimon. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol, 2005. 6(7): p. 530-41. 131. Yamamoto, S., H. Nakase, M. Matsuura, Y. Honzawa, K. Matsumura, N. Uza et al. Heparan sulfate on intestinal epithelial cells plays a critical role in intestinal crypt homeostasis via Wnt/beta-catenin signaling. Am J Physiol Gastrointest Liver Physiol, 2013. 305(3): p. G241-9. 132. Bode, L., C. Salvestrini, P.W. Park, J.P. Li, J.D. Esko, Y. Yamaguchi et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest, 2008. 118(1): p. 229-38. 133. Day, R., M. Ilyas, P. Daszak, I. Talbot, and A. Forbes. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci, 1999. 44(12): p. 2508-15. 134. Oshiro, M., K. Ono, Y. Suzuki, H. Ota, T. Katsuyama, and N. Mori. Immunohistochemical localization of heparan sulfate proteoglycan in human gastrointestinal tract. Histochem Cell Biol, 2001. 115(5): p. 373-80. 135. Wang, X., Y. Chen, Y. Song, S. Zhang, X. Xie, and X. Wang. Activated Syndecan-1 shedding contributes to mice colitis induced by dextran sulfate sodium. Dig Dis Sci, 2011. 56(4): p. 1047-56. 136. Wang, X.F., A.M. Li, J. Li, S.Y. Lin, C.D. Chen, Y.L. Zhou et al. Low molecular weight heparin relieves experimental colitis in mice by downregulating IL-1beta and inhibiting syndecan-1 shedding in the intestinal mucosa. PLoS One, 2013. 8(7): p. e66397. 137. Kato, M., S. Saunders, H. Nguyen, and M. Bernfield. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell, 1995. 6(5): p. 559-76. 138. Day, R.M., X. Hao, M. Ilyas, P. Daszak, I.C. Talbot, and A. Forbes. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch, 1999. 434(2): p. 121-5. 139. Siegmund, B., H.A. Lehr, G. Fantuzzi, and C.A. Dinarello. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A, 2001. 98(23): p. 13249-54. 140. Viennois, E., F. Chen, H. Laroui, M.T. Baker, and D. Merlin. Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res Notes, 2013. 6: p. 360. 141. Kerr, T.A., M.A. Ciorba, H. Matsumoto, V.R. Davis, J. Luo, S. Kennedy et al. Dextran sodium sulfate inhibition of real-time polymerase chain reaction amplification: a poly-A purification solution. Inflamm Bowel Dis, 2012. 18(2): p. 344-8. 142. McNamee, E.N., J.C. Masterson, P. Jedlicka, M. McManus, A. Grenz, C.B. Collins et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A, 2011. 108(40): p. 16711-6. 143. Long, T.M., A. Chakrabarti, H.J. Ezelle, S.E. Brennan-Laun, J.P. Raufman, I. Polyakova et al. RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer. Inflamm Bowel Dis, 2013. 19(6): p. 1295-305. 144. Dupaul-Chicoine, J., G. Yeretssian, K. Doiron, K.S. Bergstrom, C.R. McIntire, P.M. LeBlanc et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity, 2010. 32(3): p. 367-78. 145. Saleh, M. and G. Trinchieri. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol, 2011. 11(1): p. 9-20. 146. Martinez Gomez, J.M., L. Chen, H. Schwarz, and T. Karrasch. CD137 facilitates the resolution of acute DSS-induced colonic inflammation in mice. PLoS One, 2013. 8(9): p. e73277. 147. Pope, J.L., A.A. Bhat, A. Sharma, R. Ahmad, M. Krishnan, M.K. Washington et al. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut, 2014. 63(4): p. 622-34. 148. Zaki, M.H., K.L. Boyd, P. Vogel, M.B. Kastan, M. Lamkanfi, and T.D. Kanneganti. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity, 2010. 32(3): p. 379-91. 149. Albert, E.J. and J.S. Marshall. Aging in the absence of TLR2 is associated with reduced IFN-gamma responses in the large intestine and increased severity of induced colitis. J Leukoc Biol, 2008. 83(4): p. 833-42. 150. Mahler, M., I.J. Bristol, E.H. Leiter, A.E. Workman, E.H. Birkenmeier, C.O. Elson et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol, 1998. 274(3 Pt 1): p. G544-51. 151. Melgar, S., A. Karlsson, and E. Michaelsson. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol, 2005. 288(6): p. G1328-38. 152. Schwab, C., D. Berry, I. Rauch, I. Rennisch, J. Ramesmayer, E. Hainzl et al. Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. ISME J, 2014. 153. Shi, C., Y. Liang, J. Yang, Y. Xia, H. Chen, H. Han et al. MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PLoS One, 2013. 8(6): p. e66814. 154. Tokuyama, H., S. Ueha, M. Kurachi, K. Matsushima, F. Moriyasu, R.S. Blumberg et al. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol, 2005. 17(8): p. 1023-34. 155. Zheng, B., M.E. Morgan, H.J. van de Kant, J. Garssen, G. Folkerts, and A.D. Kraneveld. Transcriptional modulation of pattern recognition receptors in acute colitis in mice. Biochim Biophys Acta, 2013. 1832(12): p. 2162-72. 156. Zaki, M.H., P. Vogel, R.K. Malireddi, M. Body-Malapel, P.K. Anand, J. Bertin et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell, 2011. 20(5): p. 649-60. 157. Williams, K.L., C.R. Fuller, L.A. Dieleman, C.M. DaCosta, K.M. Haldeman, R.B. Sartor et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology, 2001. 120(4): p. 925-37. 158. Morgan, M.E., B. Zheng, P.J. Koelink, H.J. van de Kant, L.C. Haazen, M. van Roest et al. New perspective on dextran sodium sulfate colitis: antigen-specific T cell development during intestinal inflammation. PLoS One, 2013. 8(7): p. e69936. 159. Yan, Y., V. Kolachala, G. Dalmasso, H. Nguyen, H. Laroui, S.V. Sitaraman et al. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One, 2009. 4(6): p. e6073. 160. Sakai, H., A. Sagara, K. Matsumoto, S. Hasegawa, K. Sato, M. Nishizaki et al. 5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines. PLoS One, 2013. 8(1): p. e54788. 161. Geddes, K., J.G. Magalhaes, and S.E. Girardin. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov, 2009. 8(6): p. 465-79. 162. Davis, B.K., H. Wen, and J.P. Ting. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol, 2011. 29: p. 707-35. 163. Farache, J., I. Koren, I. Milo, I. Gurevich, K.W. Kim, E. Zigmond et al. Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation. Immunity, 2013. 38(3): p. 581-95. 164. Hu, B., E. Elinav, S. Huber, C.J. Booth, T. Strowig, C. Jin et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A, 2010. 107(50): p. 21635-40. 165. Ranganathan, P., C. Jayakumar, D.Y. Li, and G. Ramesh. UNC5B receptor deletion exacerbates DSS-induced colitis in mice by increasing epithelial cell apoptosi | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57523 | - |
dc.description.abstract | 大腸直腸癌在全世界和臺灣均是癌症死亡原因的第三名,且在臺灣大腸直腸癌已攀升為每年發生率最高之癌症。本實驗室先前的研究,於人類第四號染色體4q26鑑定NDST4於大腸直腸癌可能扮演抑癌基因的角色。NDST4屬於NDST (N-deacetylase/N-sulfotransferase)家族的一員,其功能主要是參與heparan sulfate (HS)的合成。HS支鏈會以蛋白多醣(proteoglycan)為核心蛋白鍵結其上,形成heparan sulfate proteoglycans (HSPGs)。HSPGs廣泛存在於許多組織,主要表現於細胞膜與細胞外基質。HS能夠連結許多蛋白質配體(ligand)影響訊息傳遞,進而調控許多生物活性。據此,實驗室製造Ndst4基因剔除小鼠,初步研究,此基因剔除鼠的發育和生育能力正常。根據文獻指出,Ndst4為參與HS修飾的酵素,而HSPG可藉由HS結合並調控多種細胞激素和趨化素作用,顯示Ndst4的功能可能間接調控腸道發炎反應進而影響腸炎相關大腸癌(colitis- associated cancer)之發生。因此,本論文利用dextran sodium sulfate誘發小鼠之急性大腸炎模式,以探討Ndst4於急性大腸炎發展可能扮演的角色。首先,我們選用六週至八週的野生型(wild type,WT)和Ndst4基因剔除母鼠給予含3% DSS的飲用水連續七天並觀察其疾病程度,結果顯示:相較於WT小鼠,Ndst4基因剔除小鼠體重下降程度較嚴重,且疾病活性指數(disease activity index)明顯較高。接著進行組織學檢查,發現:Ndst4基因剔除小鼠遠端大腸之組織學活性指數(histology activity index)較WT小鼠高。我們進一步定量分析小鼠大腸黏膜層之相關基因mRNA表現程度,結果顯示:Ndst4基因剔除小鼠之促發炎細胞激素Il-1β、Il-6、Tnf-α和趨化素Ccl2及Cxcl1的RNA表現程度高於WT小鼠;同時Ndst4基因剔除小鼠之T細胞相關細胞激素Ifn-γ、Il-17a、Il-22和Il-10,以及T細胞相關轉錄因子T-bet和Foxp3也有相同結果;然而Ndst4基因剔除小鼠之組織修復相關細胞激素Il-18 mRNA表現程度則低於WT小鼠。其他包括:Il-4、Il-21、Gata3和Rorγt之表現程度則與WT小鼠沒有差異。利用免疫組織化學染色分析大腸上皮細胞增生與凋亡情形,發現Ndst4基因剔除小鼠之遠端大腸上皮細胞增生程度低於WT小鼠,且遠端大腸上皮細胞凋亡程度高於WT小鼠。另外,WT小鼠與Ndst4基因剔除小鼠在誘發大腸炎後之存活分析則沒有明顯差異。綜合以上結果,Ndst4缺乏可能使特定HSPG結構修飾發生改變而影響相關發炎和組織修復調控因子的呈現與作用,進而增加個體促進大腸組織發炎的敏感性。 | zh_TW |
dc.description.abstract | Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the world and Taiwan. Nowadays, CRC is the cancer with highest annual incidence rate in Taiwan. In our previous study, we had identified NDST4 as a novel tumor suppressor gene located at chromosome 4q26 that is lost in CRC at a high frequency. NDST4 belongs to an enzyme family designated the N-deacetylase/N-sulfotransferase (heparan glucosaminyl), which are responsible for synthesis of heparan sulfate proteoglycan (HSPG) by participating in modification of heparan sulfate chains covalently attached to its core protein. HSPGs are ubiquitously expressed both on the cell surface and in the extracellular matrix, and their HS chains can regulate a wide variety of bioactive molecules, especially cytokines and chemokines. As a result, HSPGs have long been shown to participate in the pathological processes of colonic inflammation, which contributes to the development of colitis-associated cancer. Accordingly, we had generated an Ndst4 knockout (Ndst4-/-) mouse strain, which develops and reproduces normally. In the study, we aimed to explore the role of Ndst4 in acute colitis in mice. Six to eight week-old Ndst4-/- mice and wild-type (WT) mice were administered 3% dextran sodium sulfate in drinking water for seven days. We observed an increased weight loss in Ndst4-/- mice. For disease activity index, Ndst4-/- mice exhibited more severe symptoms than WT littermates. In addition, the distal colon of Ndst4-/- mice showed an increased level of histological activity index. Further, by quantitative RT-PCR analysis, we revealed that the distal colon tissues of Ndst4-/- mice displayed significantly higher expression of proinflammatory cytokines (Il-1β, Il-6, and Tnf-α) and chemokines (Ccl2 and Cxcl1) mRNA transcripts, coupled with elevated transcripts of T cell-associated cytokines (Ifn-γ, Il-17a, Il-22 and Il-10) as well as transcription factors (T-bet and Foxp3). Meanwhile, Ndst4-/- mice showed a lower expression level of Il-18 mRNA, a tissue repair-associated cytokine. Nevertheless, Il-4, Il-21, Gata3 and Rorγt expression were not different between the two groups. By immunohistochemical staining, Ndst4-/- mice exhibited decreased proliferation and enhanced apoptosis of colonic epithelial cells in distal colon after DSS-induced acute colitis. However, there was no difference in survival between WT and Ndst4-/- mice after DSS treatment. In conclusion, Ndst4 deficiency might give rise to defective modification of specific HSPGs and subsquenly alter the regulation of various ligands, resulting in the increase of susceptibility to colonic inflammation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:49:49Z (GMT). No. of bitstreams: 1 ntu-103-R01424019-1.pdf: 7139348 bytes, checksum: b38e4269d10e2b5327e0232762eb53dc (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 iii 英文摘要 v 縮寫對照表 vii 圖目錄 xii 一、研究背景 1 1、發炎性腸道疾病 1 1.1、發炎性腸道疾病之病因學 2 1.2、發炎性腸道疾病之盛行率 3 2、發炎性腸道疾病與腸道免疫系統 4 2.1、腸道上皮層 4 2.2、先天性免疫 5 2.3、先天性淋巴細胞 6 2.4、後天性免疫 8 3、發炎性腸道疾病與腸炎相關大腸癌 9 4、大腸直腸癌 11 5、抑癌基因 12 6、小鼠大腸炎動物模式 12 7、NDST(N-deacetylase/N-sulfotransferase)家族與NDST4 14 8、硫酸肝素蛋白多糖與發炎性腸道疾病 15 9、實驗室先前研究結果 17 9.1、第四號染色體之失異合性檢測 17 9.2、Ndst4基因剔除小鼠 17 9.3、AOM/DSS model 18 二、研究目標 19 三、材料與方法 20 1、實驗小鼠 20 2、DNA萃取 20 3、多重PCR 20 4、給予DSS誘發小鼠產生急性大腸炎 21 5、小鼠糞便潛血檢測 21 6、小鼠急性大腸炎臨床症狀評估 21 7、小鼠急性大腸炎病理切片分析 22 8、病理組織處理及染色 22 8.1、病理組織處理 22 8.2、蘇木紫-伊紅染色 22 8.3、免疫組織化學染色 23 9、RNA萃取 24 10、反轉錄合成互補DNA 24 11、即時定量聚合酶連鎖反應 25 12、蛋白質萃取及定量 26 13、西方墨點法 26 14、統計分析 27 15、試劑和抗體 27 四、結果 28 1、Ndst4基因剔除小鼠體重下降程度較WT小鼠嚴重且大腸縮短程度較大,同時Ndst4基因剔除小鼠疾病活性指數較高 28 2、組織學相關分析 29 2.1、Ndst4基因剔除小鼠遠端大腸之組織學活性指數較WT小鼠嚴重 29 3、分析調控發炎相關基因之mRNA於大腸黏膜層表現結果 30 3.1、Ndst4基因剔除小鼠大腸黏膜層表現促發炎細胞激素Il-1β、Il-6及Tnf-α mRNA程度高於WT小鼠,且Ndst4基因剔除小鼠表現發炎體蛋白Nlrp3 mRNA程度也高於WT小鼠 30 3.2、Ndst4基因剔除小鼠大腸黏膜層表現趨化素Ccl2及Cxcl1 mRNA程度高於WT小鼠,Ccl11 mRNA表現量則無差異 31 3.3、Ndst4基因剔除小鼠大腸黏膜層表現淋巴球相關之細胞激素Ifn-γ、Il-17a、Il-22 and Il-10 mRNA程度高於WT小鼠,Il-4和Il-21表現程度則無差異 31 3.4、Ndst4基因剔除小鼠大腸黏膜層表現轉錄因子T-bet及Foxp3 mRNA程度高於WT小鼠,而Gata3及Rorγt mRNA表現程度則無差異 32 4、分析小鼠大腸組織修復相關實驗結果 32 4.1、Ndst4基因剔除小鼠大腸黏膜層表現Il-18 mRNA程度低於WT小鼠 32 4.2、Ndst4基因剔除小鼠遠端大腸之腸道上皮細胞增生程度低於WT小鼠且細胞凋亡程度高於WT小鼠 33 5、誘發小鼠大腸炎後之存活率分析 34 五、討論 36 六、未來研究方向展望 51 七、圖 52 八、表 70 九、參考資料 71 | |
dc.language.iso | zh-TW | |
dc.title | 利用小鼠模式探討Ndst4於DSS誘發急性大腸炎之角色 | zh_TW |
dc.title | Study of the role of Ndst4 in DSS-induced acute colitis in mice | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林淑華(Shu-Wha Lin),莊雅惠(Ya-Hui Chung),徐立中(Li-Chung Hsu),林素珍(Sue-Jane Lin) | |
dc.subject.keyword | 大腸直腸癌,Ndst4,Heparan sulfate,急性大腸炎, | zh_TW |
dc.subject.keyword | Colorectal cancer,Ndst4,Heparan sulfate,Acute colitis, | en |
dc.relation.page | 87 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 6.97 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。